Opinion on Cardiovascular Devices

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Johnson & Johnson: Guidant acquisition falls apart

Johnson & Johnson's proposed $25.4 billion acquisition of Guidant has turned from bad to worse since July, with Guidant hit by a number of product recalls and even regulatory investigations. While the acquisition could still provide Johnson & Johnson with a stronger position in the lucrative medical device market, it appears the company is not willing to overpay for the asset.

Published By Datamonitor
09 Nov 2005
CommentWire
CommentWire

Boston Scientific: Guidant to rebound from product recall setbacks

Having seen safety concerns and product recalls damage its performance in 2005, the outlook for medical device maker Guidant appeared uncertain. However, boosted by the rebound of the implantable cardioverter defibrillator market and the company's pending acquisition by Boston Scientific, Guidant is now expected to regain market share in the cardiac rhythm management market.

Published By Datamonitor
13 Apr 2006
CommentWire
CommentWire

Stents: new findings could dramatically change the market

A study has suggested that the mortality risk posed by stent thrombosis is increased five-fold for STEMI patients receiving drug-eluting stents, compared to bare-metal stents. If proven, stent development is likely to move away from new drug-coated stents allowing smaller companies a chance to compete with leading players such as Boston Scientific and Johnson & Johnson.

Published By Datamonitor
06 Sep 2007
Expert View
Expert View

Can technology diminish reliance on heart transplants?

Growing risk factors in an ageing population have driven the rising prevalence of heart failure. With no new drug therapies, and existing pharmacological strategies failing to compensate for a weakening heart, other solutions must be found. Alternative technologies in particular have demonstrated promising results, suggesting we may soon eliminate the reliance on transplantation.

Published By Datamonitor
18 Jun 2008
Expert View
Expert View

AstraZeneca and Boehringer Ingelheim steal limelight at European Society of Cardiology meeting

Well crafted, positive results for AstraZeneca's Brilinta and an unexpected coup for Boehringer Ingelheim's Pradaxa dominated the headlines following this year's European Society of Cardiology's Annual Meeting in Barcelona. Both announcements have a number of important implications for the wider cardiology market, from both therapeutic and commercial perspectives.

Published By Datamonitor
03 Sep 2009

« | 1 | » »|

No help is available.